Furthermore, we found that simultaneous activation of acetylation and inhibition of O-GlcNAcylation led to near-complete suppression of Sox2 in CRC cells, suggesting that the additive effects of these PTMs on Sox2 suppression might be used in cancer treatment. This evidence concerns the gene SOX2 and cancer.